H5N1

Ganoderic acid TR is a broad-spectrum inhibitor of influenza neuraminidases (NAs), particularly H1N1 and H5N1 neuraminidases, with IC50 values of 4.6 and 10.9 μM, respectively.

Trans-Clovamide (trans-Clovamide) is a naturally occurring caffeoyl conjugate identified in the antioxidant polyphenolic fraction of cocoa (T. cacao L.) Trans-Clovamide is a potent antioxidantand that has shown neuroprotective effects (EC50s = 0.9-3.7 µM) in several in vitro models of neuronal death. Trans-Clovamide is an excellent ROS and oxygen radical scavenger and also has anti-inflammatory and neuroprotective effects. Clovamide is an anti-microbial with activity against the human pathogens influenza A subtype H5N1, Trypanosoma evansi, and Heliobacter pylori.

Dryocrassin ABBA (Dryocrassin) is a flavonoid natural product derived from Dryopteris crassirhizoma, with antiviral and antibacterial activities.

Ganoderic acid T-Q and TR are two inhibitors of H5N1 and H1N1 NAs.

H5N1 aptamer sodium is a DNA nucleic acid aptamer specifically targeting the H5N1 avian influenza virus.

MBX2329 is a specific inhibitor of HA-mediated viral entry that inhibits H1N1 virus strain high pathogenic avian influenza H5N1 virus strain.

Neuraminidase-IN-23 (33c) is a potent inhibitor of the neuraminidase enzyme (NA) targeted against influenza viruses. It exhibits inhibitory concentration (IC50) values of 0.049 μM for H1N1, 0.26 μM for H3N2, 0.17 μM for H5N1, 0.013 μM for H5N8, and 0.74 μM for H5N1-H274Y.

Neuraminidase-IN-20 (Compound 5i) is an inhibitor of neuraminidase (NA)(H5N1-H274Y) with an IC50 of 0.44 μM. It binds to the 430-cavity site of NA, disrupting the enzyme's activity.

Riamilovir sodium (Triazavirin) is a novel guanine nucleoside analogue and broad-spectrum antiviral candidate. It completely blocks viral RNA synthesis and transcription by competitively inhibiting viral RNA-dependent RNA polymerase, demonstrating exceptionally potent in vitro neutralizing activity against various strains, including H5N1 avian influenza and multidrug-resistant variants.

VF-57a (Compound 23) is an inhibitor of Influenza A virus (IAV) fusion. It exhibits potent antiviral activity against the real A/H1N1 virus, with EC50 values of 0.92 μM for the A/H1N1 PR8 strain and 0.31 μM for the A/H1N1 Virg09 strain. VF-57 significantly inhibits cell entry of HA-mediated A/H1N1 and A/H5N1 pseudoviruses and prevents HA refolding at pH 5.2. VF-57a is utilized in IAV infection research.

CL385319 is a potent inhibitor of H5N1 avian influenza A virus infection by blocking viral entry. CL-385319 is effective in inhibiting infection of highly pathogenic H5N1 influenza A virus in Madin-Darby Canine Kidney (MDCK) cells with an IC50 of 27.03±2.

CAY10766 is an antiviral compound.1It inhibits entry of influenza virus-like particles pseudotyped with hemagglutinin A (HA) from H5N1 influenza A virus into A549 cells (EC50= 0.24 μM). CAY10766 (1 μM) reduces H1N1 and H5N1 influenza A viral titers in infected MDCK cells. It also exhibits synergy with oseltamivir carboxylate in MDCK cells infected with the influenza A reporter PR8-NS1-Gluc virus.

Influenza virus-IN-4 (compound 11e) is a potent inhibitor of influenza virus neuraminidase, effective against H5N1 (IC50: 3.4 μM), H5N2 (IC50: 0.094 μM), H5N6 (IC50: 0.79 μM), and H5N8 (IC50: 0.077 μM). It inhibits NA (neuraminidase) and exhibits low cytotoxicity (CC50 > 200 μM), and is not significantly toxic to mice at 1500 mg/kg.

Neuraminidase-IN-4 (Compound 4b) is a potent inhibitor of neuraminidase (EC50: 1.59 μM) and exhibits significant antiviral activity against A/chicken/Hubei/327/2004 (H5N1-DW).

Neuraminidase-IN-7 (compound 4b), a thiophene derivative, is a potent neuraminidase inhibitor (IC50: 0.03 μM) with potential applications in influenza research.

RdRP-IN-4 (compound 11q) is an arylbenzohydrazide analogue, an orally active inhibitor of influenza A virus RNA-dependent RNA polymerase (RdRp) that directly binds the PB1 subunit of RdRp. RdRP-IN-4 inhibited H1N1 (A/PR/8/34) Flu A and Flu B strains (B/Lee/1940) in a dose-dependent manner with EC50 values of 53 nM and 20 nM, respectively. RdRP-IN-4 had a significant antiviral effect in infected mice.

Influenza virus-IN-3 (compound 9) is a potent inhibitor of selective influenza viruses, with IC50 values of 0.88 μM for H5N1, 0.10 μM for H5N2, 5.5 μM for H5N6, and 0.51 μM for H5N8. Influenza virus-IN-3 exhibits antiviral and NA (neuraminidase) inhibitory effects with low cytotoxicity (CC50 > 200 μM).

Neuraminidase-IN-3 (compound 23d) is a potent inhibitor of influenza neuraminidase (NA) with IC50 values of 0.73 nM for H1N1, 0.26 nM for H5N1, and 0.63 nM for H5N8 NAs.

Neuraminidase-IN-10 is a neuraminidase inhibitor that exhibits anti-influenza effects and is able to act on H1N1 (IC50: 2.6 nM), H5N1 (IC50: 5.1 nM) and H5N8 (IC50: 1.65 nM).

Neuraminidase-IN-9 (Compound 6l) is a potent inhibitor of influenza virus neuraminidase, targeting H5N1 (IC50: 0.12 μM), H5N2 (IC50: 0.049 μM), and H5N6 (IC50: 0.16 μM).

Neuraminidase-IN-11 (15e) is a selective and potent neuraminidase (NA) inhibitor, effective against the neuraminidase of H1N1 virus (IC50: 4.7 nM), H5N1 virus (IC50: 8.46 nM), and H5N8 virus (IC50: 1.5 nM).

LUN15104 is a novel hemagglutinin (HA) protein inhibitor, inhibiting entry and replication of diverse influenza viruses via the HA protein, showing potent antiviral activity against diverse H1N1, H5N1, and H3N2 influenza viruses encoding HA proteins from both groups 1 and 2. This product has no formal name. For the convenience of scientific communication, we named it by combining its InChi Key (3 letters from the first letter of each section) with the last 5 digit of its CAS#) according to MedKoo Chemical Nomenclature (https://www.medkoo.com/page/naming).

Pimodivir, also known as VX-787, JNJ-872, is a novel inhibitor of influenza virus replication that blocks the PB2 cap-snatching activity of the influenza viral polymerase complex. VX-787 binds the cap-binding domain of the PB2 subunit with a KD (dissociation constant) of 24 nM as determined by isothermal titration calorimetry (ITC). The cell-based EC50 (the concentration of compound that ensures 50% cell viability of an uninfected control) for VX-787 is 1.6 nM in a cytopathic effect (CPE) assay, with a similar EC50 in a viral RNA replication assay. VX-787 is active against a diverse panel of influenza A virus strains, including H1N1pdm09 and H5N1 strains, as well as strains with reduced susceptibility to neuraminidase inhibitors (NAIs).

FA-613 is a pyrimidine synthesis inhibitor which exhibits low micromolar antiviral activity against various influenza A and B virus strains, including the highly pathogenic influenza A strains H5N1 and H7N9, enterovirus A71, respiratory syncytial virus, human rhinovirus A, SARS- and MERS-coronavirus.